DIFFERENCES IN THE EFFECTIVENESS OF SELECTIVE ALPHA BLOCKER THERAPY COMBINED WITH 5-ALPHA REDUCTASE INHIBITOR ON IPSS VALUE OF BPH LUTS PATIENTS

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

PDF
Published 2020-07-20
Septa Surya Wahyudi Nuno Febrian Probosutiksna Enny Suswati

Abstract

Objective: The purpose of this study is to know the differences in effectiveness between SAB administration with combination 5-ARI administration assessed by IPSS evaluation in BPH LUTS patients. Material & Methods: This observational analytic with a cross-sectional design study had been done to 50 BPH LUTS patients that obtained at Paru Jember, Bina Sehat Jember, and Bhayangkara Bondowoso Hospital. These samples had got by simple random sampling method and include in inclusion with exclusion criteria freely. Results: This comparison study between the type of medical therapy administration and total IPSS decrease, IPSS-voiding decrease, IPSS-storage decrease, IPSS-QoL, and prostate volume give significancies as follows: p=0.002; p<0.001; p<0.001; p<0.05; p<0.001. Conclusion: There are significant differences between the type of medical therapy (SAB or 5-ARI combination) and total IPSS decrease, IPSS-voiding decrease, IPSS-storage decrease, IPSS-QoL, and prostate volume.


##plugins.themes.bootstrap3.article.details##

Keywords

Benign prostatic hyperplasia (BPH), Lower Urinary Tract Syndrome (LUTS), International Prostatic Symptom Score (IPSS), Selective Alpha Blocker, 5-Alpha Reductase Inhibitor

References

Vuichoud C, K. R. Loughlin. Benign prostatic hyperplasia: epidemiology, economics, and evaluation. Can J Urol. 2015; 22(1): 1-6.

Speakman M., R. Kirby, S. Doyle, C. Ioannou. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)–focus on the UK. BJU international. 2015; 115(4): 508-519.

Porru D, H. Jallous, V. Cavalli, F. Sallusto, B. Rovereto. Prognostic value of a combination of IPSS, flow rate, and residual urine volume compared to pressure-flow studies in the preoperative evaluation of symptomatic BPH. European urology. 2002; 41(3): 246-249.

Amalia R. Faktor-faktor risiko terjadinya pembesaran prostat jinak (studi kasus di RS dr. Kariadi, RSI Sultan Agung, RS Roesmani Semarang). Jurnal Epidemiologi. 2008.

Asseldonk B. V, J. Barkin, D. S. Elterman. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol. 2015; 22(1): 7-17.

Kaplan S. A, J. D. McConnell, C. G. Roehrborn, A. G. Meehan, M. W. Lee, W. R. Noble. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. The Journal of urology. 2006; 175(1): 217-220.

Roehrborn C G. Pathology of benign prostatic hyperplasia. International journal of impotence research. 2008; 20(S3): S11.

Wilt T. J, J. N’dow. Benign prostatic hyperplasia. Part 2-management. BMJ. 2008; 336(7637): 206-210.

Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. The Journal of urology. 2003. 169(4): 1520-1525.

Mobley D, A. Feibus, N. Baum. Benign prostatic hyperplasia and urinary symptoms: evaluation and treatment. Postgraduate medicine. 2015; 127(3): 301-307.

Section
Articles
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University